CRDF

Cardiff Oncology, Inc. (CRDF) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel therapies based on Polo-like Kinase 1 (PLK1) inhibition. The company's lead asset is onvansertib, an oral PLK1 inhibitor currently in clinical trials for RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and metastatic triple-negative breast cancer (mTNBC).

Key Financial Metrics

Note: All figures in millions unless otherwise noted. Revenue consists of royalty income from legacy licenses unrelated to onvansertib.

Material Changes vs. Prior Period

• Liquidity Position: Cash and cash equivalents decreased significantly from $51.5 million at year-end 2024 to $10.1 million at September 30, 2025. However, total liquid assets (including short-term investments) remain at $60.6 million.
• Operating Expenses:
  • Q3 Comparison: Total operating expenses decreased by $0.68 million quarter-over-quarter, driven primarily by a $1.9 million reduction in clinical trial and outside service costs.
  • YTD Comparison: Total operating expenses increased by $4.87 million year-over-year. Research and Development (R&D) expenses rose by $3.1 million due to costs associated with the CRDF-004 clinical trial. Selling, General, and Administrative (SG&A) expenses increased by $1.8 million, largely due to an employee severance agreement and increased professional fees.
• Stock-Based Compensation: Increased to $4.4 million for the nine months ended September 30, 2025, compared to $3.6 million in the prior year period, attributed to new stock option grants.

Outlook, Risks, and Management Commentary

• Clinical Progress:
  • mCRC (CRDF-004): Data presented in July 2025 showed improved Objective Response Rates (ORR) for onvansertib combined with standard-of-care (SoC) compared to SoC alone (42-49% vs. 30% confirmed ORR). The company plans to initiate a Phase 3 registrational trial (CRDF-005) contingent on these results.
  • mTNBC: Positive data presented in June 2025 showed a 40% ORR for onvansertib plus paclitaxel in metastatic triple-negative breast cancer.
  • mPDAC & SCLC: Investigator-initiated trials are ongoing or open for enrollment.
• Liquidity Outlook: Management believes current cash resources ($60.6 million) are sufficient to fund operations into the first quarter of 2027. The company expects to continue incurring losses and will require additional capital to advance clinical programs.
• Risks:
  • Funding: No guarantee that additional funding will be available on acceptable terms; equity raises may result in dilution.
  • Regulatory: Potential government shutdowns or funding inadequacies at the FDA could delay product reviews and approvals.
  • Development: High risk associated with clinical trial outcomes and regulatory approval timelines.

Investor Verification Checklist

• Cash Runway: Verify the specific burn rate and confirm the "first quarter of 2027" funding projection against current cash balances of $60.6 million.
• CRDF-004 Trial Status: Confirm the timeline and criteria for initiating the planned Phase 3 trial (CRDF-005) based on the interim Phase 2 data.
• Severance Impact: Review the details of the employee severance agreement recorded in SG&A to determine if it represents a one-time cost or a recurring liability.
• Investment Portfolio: Assess the composition of short-term investments ($50.5 million) and potential impact of interest rate changes on unrealized gains/losses.
• Dilution Risk: Monitor outstanding options (11.2 million) and warrants (1.1 million) for potential dilution in future capital raises.